Publications - Novocure

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy

mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.

delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.

treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media

media gallery

Featured Stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

21.50

0.45

last update 9/21/2017 12:00AM
careers

working with us

our locations

current job listings

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.

Proceedings of the National Academy of Sciences, Volume 104, No. 24, June 12, 2007.

Read Article

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

European Journal of Cancer, Volume 48, No. 12, 2012.

Read Article

Delayed response and survival from NovoTTF-100A in recurrent GBM.

Medical Oncology, Volume 3, No. 338, January 2013.

Read Article

Response assessment of NovoTTF-100A vs best physician’s choice of chemotherapy in recurrent glioblastoma.

Cancer Medicine, Volume 3, No. 3, 2014.

Read Article

Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.

Seminars in Oncology, Volume 41, S1 – S14, June, 2014.

Read Article

Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy.

Seminars in Oncology, Volume 41, S25 – S34, October, 2014.

Read Article

Response patterns of recurrent glioblastomas treated With Tumor Treating Fields.

Seminars in Oncology, Volume 41, S14 – S24, October, 2014.

Read Article

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe).

Seminars in Oncology, Volume 41, S4 – S13, October, 2014.

Read Article

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy
- mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.
- delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.
- treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media
- media gallery
- Featured Stories
investor relations
careers